Listing analysis and research matching China:
China's biopharmaceutical patent footprint
Chinese inventors are increasing filing for biotechnology patents with the American USPTO, peaking at 51 patents in 2003. Many of these patents are being filed by inventors based in Beijing, Shanghai and Hong Kong. A large proportion of the biotechnology-related patents are for antibody technology (42%), and a large proportion are being assigned to university institutions.
Biopharmaceutical partnering in China
Multinational pharmaceutical companies are increasingly investing in China through alliances and the building of new centres. Much of the investment is to supplement rather than replace the research and development already occurring outside China and is focused on development and processes than be easily codified and regulated.
India and China's place in biotechnology innovation
With their growing economies, well-educated populations and low-cost of labour India and China are emerging as attractive places for potential biotechnology investment. Many sizeable biotechnology companies attending the Bio.org conference held in Boston in May 2007 indicated they were keen to enter India and China. Increasing pressures to fill product pipelines and reduce the cost of development make these countries appealling locations for biopharmaceutical partnerships and investment. How far foreign companies will invest in the two countries in the near future will be highly dependent on their compliance with international standards in manufacturing and clinical testing and their protection of intellectual property. Research by Silico shows that while India and China could prove powerful in the field of biogenerics and vaccines, their level of patenting remains modest. raising questions about their role in biopharmaceutical innovation.
India and China's biogeneric and vaccine strengths
Today many biotechnology analysts are pointing to China and India as becoming strategically important for biotechnology growth and investment. For the forseeable future the strength of Indian and Chinese biotechnology will be confined to the area of generics and vaccines where they have already established some strengths
GSK announces Chinese neurology research center
GlaxoSmithKline has announced a new Chinese research and development centre to add to its 32 research sites around the world. The centre is to be based in Shanghai and will be focused on the development of drugs to treat neurodegenerative disorders such as multiple sclerosis, Parkinson's disease and Alzheimer's disease.
Novartis switching planned research investments from India to China
Novartis is reported to be switching hundreds of millions of dollars in planned research investments from India in the next few years in response to a court ruling rejecting it's challenge to a section of the country's Patents Act that aims to restrict certain kinds of patents. Novartis is planning to move the investments to China.
